nach oben

Diabetology International

Erschienen in:

01.06.2013 | Original Article

Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia

verfasst von: Hiroko Mori, Yosuke Okada, Yoshiya Tanaka

Erschienen in: Diabetology International | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Aims/introduction

We investigated the effects of three different statins in patients with type 2 diabetes mellitus and hypercholesterolemia.

Materials and methods

Patients with type 2 diabetes mellitus and low-density lipoprotein-cholesterol level of more than or equal to 100 mg/dL were treated at random with either atorvastatin (10 mg/day, n = 42), rosuvastatin (5 mg/day, n = 37) or pravastatin (10 mg/day, n = 38) for 3 months and changes in serum lipid profile and inflammatory markers were assessed.

Results

Low-density lipoprotein-cholesterol, small dense low-density lipoprotein and remnant-like particle cholesterol were significantly decreased from baseline in 3 groups. Atorvastatin and rosuvastatin significantly decreased high-sensitivity C-reactive protein. Rosuvastatin significantly decreased monocyte chemoattractant protein-1, while atorvastatin significantly increased estimated glomerular filtration rate (eGFR), but there were no significant intergroup differences in both parameters.

Conclusions

Atorvastatin and rosuvastatin significantly highly decreased low-density lipoprotein-cholesterol, remnant-like particle cholesterol, small dense low-density lipoprotein as well as high-sensitivity C-reactive protein than pravastatin and atorvastatin also had a potency in improve eGFR in patients with type 2 diabetes mellitus.

Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.PubMedCrossRef

Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227–39.PubMedCrossRef

Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):E1–40.PubMedCrossRef

Teramoto T, Sasaki J, Ueshima H, et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb. 2007;14:155–8.PubMedCrossRef

Bahadir MA, Oguz A, Uzunlulu M, et al. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb. 2009;16:684–90.PubMedCrossRef

Otokozawa S, Ai M, Van Himbergen T, et al. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis. 2009;205:197–201.PubMedCrossRef

Mason RP, Walter MF, Day CA, et al. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem. 2006;281:9337–45.PubMedCrossRef

Thongtang N, Ai M, Otokozawa S, et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011;107:387–92.PubMedCrossRef

Puccetti L, Santilli F, Pasqui AL, et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis. 2011;214:122–8.PubMedCrossRef

10.

Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131–9.PubMedCrossRef

11.

Zhang L, Zhang S, Jiang H, et al. Effect of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol. 2010;34:117–23.PubMedCrossRef

12.

Biffi A, Devan WJ, Anderson CD, et al. Statin treatment and functional outcome after ischemic stroke: case–control and meta-analysis. Stroke. 2011;42:1314–9.PubMedCrossRef

13.

Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295:1556–65.PubMedCrossRef

14.

The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–228.

15.

Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330–41.PubMedCrossRef

16.

Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105:69–76.PubMedCrossRef

17.

Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol. 2003;91(5A):3C–10C. discussion 10C.PubMedCrossRef

18.

Schneck DW, Knopp RH, Ballantyne CM, et al. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003;91:33–41.PubMedCrossRef

19.

Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152–60.PubMedCrossRef

20.

Brunetti ND, Maulucci G, Casavecchia GP, et al. Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg. J Interv Cardiol. 2007;20:481–7.PubMedCrossRef

21.

Yanagi K, Monden T, Ikeda S, et al. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. Adv Ther. 2011;28:160–71.PubMedCrossRef

22.

Atorvastatin study group in Korea. Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients. Korean J Intern Med. 2008;23:22–9.CrossRef

23.

Yamada S, Yanagawa T, Sasamoto K, et al. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. Metabolism. 2006;55:67–71.PubMedCrossRef

24.

Takebayashi K, Matsumoto S, Wakabayashi S, et al. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism. 2005;54:1225–9.PubMedCrossRef

25.

Forst T, Wilhelm B, Pfützner A, et al. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res. 2008;5:298–303.PubMedCrossRef

26.

Blanco-Colio LM, Martín-Ventura JL, de Teresa E, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J. 2007;153:881–8.PubMedCrossRef

27.

Palaniswamy C, Selvaraj DR, Selvaraj T, et al. Mechanisms underlying pleiotropic effects of statins. Am J Ther. 2010;17:75–8.PubMedCrossRef

28.

Koh KK, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209–16.PubMedCrossRef

29.

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRef

30.

Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.PubMedCrossRef

31.

Cachofeiro V, Goicochea M, de Vinuesa SG, et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;111:S4–9.PubMedCrossRef

32.

Colhoun HM, Betteridge DJ, Durrington PN, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54:810–9.PubMedCrossRef

33.

Sawara Y, Takei T, Uchida K, et al. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease. Intern Med. 2008;47:1505–10.PubMedCrossRef

34.

Sorof J, Berne C, Siewert-Delle A, et al. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;72:81–7.PubMedCrossRef

Titel: Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia
verfasst von: Hiroko Mori
Yosuke Okada
Yoshiya Tanaka
Publikationsdatum: 01.06.2013
Verlag: Springer Japan
Erschienen in: Diabetology International / Ausgabe 2/2013
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI: https://doi.org/10.1007/s13340-012-0103-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/introduction

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Association between diabetes and hearing impairment in a large health check-up population

Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients

Diagnostic criteria of diabetes

Survey of urinary albumin level and estimated GFR in Japanese patients with type 2 diabetes mellitus

Mitochondria toxicity of antihyperlipidemic agents bezafibrate and fenofibrate